Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

Dholaria, Bhagirathbhai; Savani, Bipin B.; Labopin, Myriam; Luznik, Leo; Ruggeri, Annalisa; Mielke, Stephan; Malki, Monzr M.M. Al; Kongtim, Piyanuch; Fuchs, Ephraim J.; Huang, Xiao Jun; Locatelli, Franco; Aversa, Franco; Castagna, Luca; Bacigalupo, Andrea; Martelli, Massimo F.; Blaise, Didier; Soussan, Patrick Ben; Arnault, Yolande; Handgretinger, Rupert; Roy, Denis; O’Donnell, Paul V.; Bashey, Asad; Solomon, Scott R.; Romee, Rizwan; Lewalle, Philippe; Gayoso, Jorge; Maschan, Michael; Lazarus, Hillard; Ballen, Karen K.; Giebel, Sebastian; Baron, Frédéric; Ciceri, Fabio; Esteve, Jordi; Gorin, Norbert Claude; Spyridonidis, Alexandros; Schmid, Christoph; Ciurea, Stefan O.; Nagler, Arnon; Mohty, Mohamad

doi:10.3324/haematol.2019.219790

Cited by 61 publications

(41 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of a prophylactic or pre-emptive strategy, a few small studies comparing T-repleted haploidentical or HLA-identical DLIs in refractory or very high-risk AML observed higher rates of acute GVHD and NRM ( 24 , 25 ), while a large recent prospective study including 189 AL patients in first complete remission reported a prolonged graft and relapse-free survival after haploidentical HCT with an homogeneous ATG-based prophylaxis followed by DLI in comparison with HCT from matched related donors ( 26 ). Clinical trials are needed to establish the optimal timing and cell dose in both therapeutic and prophylactic settings after haploidentical HCT and the relationship with GVHD and disease response ( 27 ).…”

Section: Discussionmentioning

confidence: 99%

Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

et al. 2020

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…In patients with relapsed/refractory Hodgkin disease, HAPLO transplantation has been credited for offering the most potent antitumor effect . The EBMT ALWP has recently proposed consensus recommendations for clinical applications of donor lymphocyte infusions from HAPLO donors and has recommended its use as safe and effective in patients in relapse or who still have detectable MRD and/or mixed donor chimerism after a HAPLO transplantation . For many teams, HAPLO donors are becoming the first choice when an alternative donor is sought.…”

Section: Discussionmentioning

confidence: 99%

“…25,44 The EBMT ALWP has recently proposed consensus recommendations for clinical applications of donor lymphocyte infusions from HAPLO donors and has recommended its use as safe and effective in patients in relapse or who still have detectable MRD and/or mixed donor chimerism after a HAPLO transplantation. 45 For many teams, HAPLO donors are becoming the first choice when an alternative donor is sought. The question whether a HAPLO donor might produce outcomes similar to those produced by genoidentical donors has recently been investigated retrospectively by the EBMT in a matched-pair analysis of 2654 adult patients with intermediate-risk and high-risk leukemia.…”

Section: Discussionmentioning

confidence: 99%

Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation

Gorin

Labopin

Blaise

et al. 2019

Cancer

Self Cite

View full text Add to dashboard Cite

Background In adult patients with acute myeloid leukemia (AML), a matched sibling donor (MSD) is considered the first choice for an allogeneic transplantation. However, a female donor for a male recipient is a poor prognostic factor. The authors compared haploidentical (HAPLO) donors with female MSDs. Methods In total, 834 men underwent allogenic transplantation from a female MSD, and 232 men underwent allogenic transplantation from a HAPLO donor. Of these, 86% of HAPLO recipients and 3% of MSD recipients received graft‐versus‐host disease (GVHD) prophylaxis posttransplantation with high‐dose cyclophosphamide. A significant qualitative interaction was observed between donor type and cytogenetics, Therefore, the analyses were stratified on cytogenetics. Results Of the men with intermediate‐risk AML, 638 received transplantation from a female MSD, and 160 received transplantation from a HAPLO donor. In multivariate analysis, poor risk factors were a HAPLO donor versus an MSD for nonrelapse mortality (hazard ratio [HR], 1.7; P = .02) and patient age for nonrelapse mortality and overall survival (HR, 1.22 [P = .02] and 1.15 [P = .02], respectively). HAPLO transplantation resulted in less chronic GVHD (HR, 0.43; P < 10−4) but lower leukemia‐free survival (HR, 1.7; P = .04). The GVHD/relapse‐free survival (GRFS) was not different. Of the men with high‐risk AML, 196 received transplantation from a female MSD, and 72 received transplantation from a HAPLO donor. By multivariate analysis, HAPLO recipients had a lower incidence of relapse (HR, 0.40; P = .004), better leukemia‐free survival (HR, 0.46; P = .003), better overall survival (HR, 0.43; P = .003), and better GRFS (HR, 0.54; P = .006). Conclusions In men who have intermediate‐risk AML, allogenic transplantation from a sister MSD or a HAPLO donor produces similar GRFS. However, in men who have high‐risk AML, a HAPLO donor combined with prophylactic high‐dose cyclophosphamide posttransplantation may be a better choice.

show abstract

“…Donors were no longer a problem for most EMS patients [20,21]. Patients with high-risk myeloid malignancies may benefit from a prophylactic haplo-DLI, which should ideally be used in the setting of a clinical trial [22].…”

Section: Discussionmentioning

confidence: 99%

A case of a patient characterized by t(8;22)(p11;q11) and BCR/FGFR1 fusion gene, who was successfully treated with haploidentical hematopoietic stem cell transplantation

et al. 2021

View full text Add to dashboard Cite

Objective: The 8p11 myeloproliferative syndrome [EMS] is a rare myeloproliferative disorder which usually develops rapidly with chromosomal translocation of the fibroblast growth factor receptor 1 gene. The gene has 15 fusion partners, including the breakpoint cluster region (BCR) gene on chromosome 22. Of all the tests available, chromosome karyotype determination is the most important for the diagnosis of EMS. Here, we describe one case of a patient characterized by marked increase of white blood cells and thrombocytopenia and diagnosed as EMS with t(8;22)(p11;q11) by chromosome karyotype. Methods: 28-year-old man was referred to our hospital. He had a onemonth history of intermittent coughing and a small amount of expectoration after catching a cold. As an outpatient, his complete blood count showed: WBC was 130.04 × 10 9 /L with 80.20% granulocytes.Hematologic investigations, bone marrow analysis and genomic DNA sequencing studies were performed. Results: Despite additional chromosomal abnormalities,the patient progressed rapidly with a B blast cell clone in one month. After diagnosis inthree months, the patient underwent the haplo-identical BMT of his brother, followed up for three years, and had a high rate of survival. Conclusions: Our report provides a definite conceptual framework for a better understanding of the characteristics of The 8p11 myeloproliferative syndrome [EMS].

show abstract

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

Cited by 61 publications

References 98 publications

Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation

A case of a patient characterized by t(8;22)(p11;q11) and BCR/FGFR1 fusion gene, who was successfully treated with haploidentical hematopoietic stem cell transplantation

Contact Info

Product

Resources

About